Home › Compare › LTTGF vs ABBV

LTTGF vs ABBV: Dividend Comparison 2026

LTTGF yields 200000000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LTTGF wins by $4.875657285131069e+59M in total portfolio value
10 years
LTTGF
LTTGF
● Live price
200000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.875657285131069e+59M
Annual income
$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00
Full LTTGF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — LTTGF vs ABBV

📍 LTTGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLTTGFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LTTGF + ABBV cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
LTTGF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LTTGF
Annual income on $10K today (after 15% tax)
$17,000,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, LTTGF beats the other by $414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LTTGF + ABBV for your $10,000?

LTTGF: 50%ABBV: 50%
100% ABBV50/50100% LTTGF
Portfolio after 10yr
$2.4378286425655345e+59M
Annual income
$243,782,624,477,893,130,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

LTTGF
No analyst data
Altman Z
-16.1
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LTTGF buys
0
ABBV buys
0
No recent congressional trades found for LTTGF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLTTGFABBV
Forward yield200000000.00% ✓3.06%
Annual dividend / share$2.00$6.65 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6% ✓
Portfolio after 10y$4.875657285131069e+59M$102.3K ✓
Annual income after 10y$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓$24,771.77
Total dividends collected$4.875656971401711e+59M$61.0K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LTTGF vs ABBV ($10,000, DRIP)

YearLTTGF PortfolioLTTGF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$20,000,010,700$20,000,000,000.00$11,550$430.00+$20000.00M → LTTGF
2$37,383,218,970,104,910$37,383,197,570,093,464.00$13,472$627.96+$37383218970.09M → LTTGF
3$65,303,942,472,059,150,000,000$65,303,902,472,014,860,000,000.00$15,906$926.08+$65303942472059152.00M → LTTGF
4$106,615,009,060,306,890,000,000,000,000$106,614,939,185,088,440,000,000,000,000.00$19,071$1,382.55+$1.0661500906030689e+23M → LTTGF
5$162,672,273,967,082,950,000,000,000,000,000,000$162,672,159,889,023,270,000,000,000,000,000,000.00$23,302$2,095.81+$1.6267227396708296e+29M → LTTGF
6$231,966,340,306,755,300,000,000,000,000,000,000,000,000$231,966,166,247,422,140,000,000,000,000,000,000,000,000.00$29,150$3,237.93+$2.319663403067553e+35M → LTTGF
7$309,138,182,305,146,600,000,000,000,000,000,000,000,000,000,000$309,137,934,101,162,400,000,000,000,000,000,000,000,000,000,000.00$37,536$5,121.41+$3.091381823051466e+41M → LTTGF
8$385,031,777,252,258,400,000,000,000,000,000,000,000,000,000,000,000,000$385,031,446,474,403,340,000,000,000,000,000,000,000,000,000,000,000,000.00$50,079$8,338.38+$3.850317772522584e+47M → LTTGF
9$448,184,411,799,345,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000$448,183,999,815,344,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00$69,753$14,065.80+$4.481844117993459e+53M → LTTGF
10$487,565,728,513,106,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00$102,337$24,771.77+$4.875657285131069e+59M → LTTGF

LTTGF vs ABBV: Complete Analysis 2026

LTTGF — Stock

LottoGopher Holdings Inc. provides lottery messenger services in California. Its services allow users to order and manage lottery tickets online using a debit or credit card. The company also provides free membership and paid subscription services to conduct its online sweepstakes games. LottoGopher Holdings Inc. was formerly known as Red Hat Investments Inc. The company was incorporated in 2016 and is headquartered in Vancouver, Canada.

Full LTTGF Calculator →

ABBV — Healthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this LTTGF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LTTGF vs SCHDLTTGF vs JEPILTTGF vs OLTTGF vs KOLTTGF vs MAINLTTGF vs JNJLTTGF vs MRKLTTGF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.